Welcome to our dedicated page for Nemaura Med news (Ticker: NMRD), a resource for investors and traders seeking the latest updates and insights on Nemaura Med stock.
Nemaura Medical Inc. (NMRD) delivers innovative medical technology solutions focused on non-invasive health monitoring. This news hub provides investors and healthcare professionals with essential updates on the company's pioneering products like SugarBEAT glucose monitoring system and the Why Wait wellness platform.
Access all official announcements including regulatory milestones, partnership developments, and financial disclosures in one centralized location. Our curated feed features updates on clinical trial progress, manufacturing expansions, and strategic initiatives that shape Nemaura Medical's position in the diabetes care market.
Discover critical information about product launches, intellectual property updates, and leadership changes directly from corporate sources. For stakeholders tracking medical device innovation, this resource offers timely insights into Nemaura Medical's contributions to personalized healthcare solutions.
Bookmark this page for streamlined access to verified NMRD news. Check back regularly for updates on technological advancements and market developments from this forward-thinking medical technology company.
Nemaura Medical, Inc. (NASDAQ: NMRD) announced that CEO Dr. Faz Chowdhury will engage in a fireside chat on March 29, 2023, at 10 AM ET, hosted by EF Hutton's analyst Constantine Davides. The chat will explore Nemaura's innovative glucose monitoring device, digital health solutions, commercial strategy, and early patient data from their UK pilot program.
The company is developing non-invasive wearable sensors and has submitted a PMA for its sugarBEAT® device to the FDA. Nemaura aims to capitalize on a growing global diabetes market projected to reach nearly $59 billion by 2025.
Nemaura Medical (NASDAQ: NMRD) announced the inclusion of injectable insulin in its DuoPack Commercial License Agreement with MySugarWatch DuoPack Limited. This agreement allows Nemaura's non-invasive wearable sensors to be paired with insulin and other Type 2 diabetes medications, enhancing patient care through a holistic approach. The collaboration aims to provide access to a continuous glucose monitoring-guided insulin dosage system, potentially reducing hospital admissions and improving outcomes for approximately 4 million older diabetes patients in the UK and EU. Nemaura continues to innovate in the diabetes management market, expected to exceed $59 billion by 2025.
FAQ
What is the current stock price of Nemaura Med (NMRD)?
What is the market cap of Nemaura Med (NMRD)?
